Abstract:As the most potent antigen-presenting cells, Dendritic cells (DCs), capable of inducing immune responses from naive T cells, are operative tools for tumor immunotherapy. Derived DCs are extremely effective in capturing and presentation of antigens to T cells and play a key role in the induction of cytotoxic T lymphocytes (CTLs). In vitro culture system containing the combination of GM-CSF, IL-4 and TNF-α cytokine can affect CD14 + progenitor cells from mononuclear cells (MNCs) of peripheral blood (PB) developing into functional DCs, which have enough quantities for application in vitro researches and clinical practices. Multiple myeloma cells(MM)are able to secrete a great quantity of immunoglobulin (Ig) expressing idiotypic antigen called idiotype (Id) in its mutational hotspot. This kind of idiotypic structure regions also expressing on the surface of MM cells are high specific autologous tumor associated antigen (TAA). The combination use of DCs and tumor specific antigen can improve the immunogenicity of MM cells and stimulate specific anti-tumor immunological response effectively, so by using this new kind of DC tumor vaccine, following high dose chemical therapy, the tiny residual pathological changes might be cleared totally in the future. To investigate the specific antitumor immune response induced by Id-pulsed dendritic cells(DCs) in vitro. DCs were generated from peripheral blood monocytes of the multiple myeloma(MM) patients using GM-CSF, IL-4, and TNF-α. pulsed with idiotype protein at the immature stage, DCs could activate T cells to become tumor specific cytotoxic T lymphocytes (CTLs). The morphologic characteristics of those cells were observed with light and electron microscopes. The phenotypic figures were analyzed with FACS analysis. Methy-thiazoly-Tetrazolium (MTT) assay was employed to evaluate the effect of proliferation of autologous T cells and the inhibition rate of CTL on MM cells. DCs precursors in peripheral blood could be induced to typical mature DCs in medium containing GM-CSF, IL-4 and TNF-α. Mature DCs with Id could operatively increase proliferation of the autologous T cells and active naive T cells to become tumor specialized CTLs. Any doses of CTLs had significant inhibition or killing ability on autologous MM cells. These results suggest in suitable cytokine environment, the precursors in peripheral blood of MM patients could be induced to functional DCs, and vaccination with Id-pulsed DCs could induce active antitumor immune response. Multiple cycles of immunization using DC as APC in vitro can be beneficial in generating antigen- specific T cells from normal PBMC, and Id an auto-specific tumor antigen, can be got with ammonium sulfate four-step precipitated method, By digestion of pepsin and affinity chromatography so as to stimulate MM specific immunological responce, and Id-pulsed mature DCs from MM patients can stimulate not only the proliferation of autologous T cells, but also the specific CTL immune response against autologous MM cells. In addition, in vitro immunization may provide an alternative approach to in vivo immunization of MM. We believe that DCs vaccine can bring the breakthrough of therapy to MM in the near future.

Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96

Leukemia: Derived Heat Shock Protein Gp96-Peptide Complex Contribution to T Cell and Dendritic Cell Activation

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.

T Cell-Based Targeted Immunotherapies For Patients With Multiple Myeloma

Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma.

Specific Cell Immune Response Mediated by Myeloma Lysate Pulsed Dendritic Cells

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.

The Research of Specific Cytotoxicity T Lymphocyte Response Mediated by Myeloma Antigen-Pulsed Dendritic Cells

Enhanced Interferon-Gamma Secretion and Antitumor Activity of T-Lymphocytes Activated by Dendritic Cells Loaded with Glycoengineered Myeloma Antigens

Anti-Myeloma Effects Induced by Myeloma Idiotype Pulsed Dendritic Cells in Vitro.

The anti-leukemia effect of heat shock protein-peptide complex-96

Targeted immunotherapy: harnessing the immune system to battle multiple myeloma

Immune Responses of Dendritic Cells Plused with Myeloma Antigen

Progress of Cellular and Vaccine Immunotherapy in Multiple Myeloma

Membrane-bound HSP70-engineered Myeloma Cell-Derived Exosomes Stimulate More Efficient CD8(+) CTL- and NK-mediated Antitumour Immunity Than Exosomes Released from Heat-Shocked Tumour Cells Expressing Cytoplasmic HSP70.

Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma

Peptide-based Immunotherapy for Multiple Myeloma: Current Approaches.

A novel multi‐epitope vaccine from MMSA‐1 and DKK1 for multiple myeloma immunotherapy

Modulatory Effects of Tumor-Derived Heat Shock Protein in DNA Vaccination Against Nasopharyngeal Carcinoma

[Induction of Active Antitumor Immune Response by Myeloma Idiotype Protein-Pulsed Dendritic Cells].

B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.